Skip to main content
. 2022 Feb 25;17(2):253–267. doi: 10.1016/j.ajps.2022.01.002

Fig. 8.

Fig 8

In vivo antitumour efficacy in tumour-bearing BABL/C nude mice. (A) Schematic illustration of in vivo antitumour efficacy of ZnO2@Lip-ICG NPs; (B) photograph of tumour tissues; (1: Saline; 2: ZnO2@Lip; 3: Free ICG; 4: ICG@Lip; 5: ZnO2@Lip-ICG; 6: Saline+Laser; 7: ZnO2@Lip+Laser; 8: Free ICG+Laser; 9: ICG@Lip+Laser; 10: ZnO2@Lip-ICG+Laser); (C) Tumour weight, (D) tumour volume and (E) body weight of CNE-2 tumour-bearing mice in each group (n = 5), * P < 0.05, ** P < 0.01.